These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 31285829)

  • 21. Increasing dietary phosphorus intake from food additives: potential for negative impact on bone health.
    Takeda E; Yamamoto H; Yamanaka-Okumura H; Taketani Y
    Adv Nutr; 2014 Jan; 5(1):92-7. PubMed ID: 24425727
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chronic kidney disease mineral bone disorder and health-related quality of life among incident end-stage renal-disease patients.
    Johansen KL; Chertow GM
    J Ren Nutr; 2007 Sep; 17(5):305-13. PubMed ID: 17720099
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hyperparathyroidism, Serum Phosphorus and Dietary Intake in Hemodialysis Patients: Is There a Novel Relationship?
    Garagarza C; Valente A; Queirós C; Neto IP; Sebastião J; Gomes M; Ferreira A
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.
    Copland M; Komenda P; Weinhandl ED; McCullough PA; Morfin JA
    Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-World Experience of Using Etelcalcetide for Secondary Hyperparathyroidism in Community-Based Hemodialysis Centers in Singapore.
    Khan BA; Qu X; Hua Y; Javaid MM
    Cureus; 2023 Nov; 15(11):e48186. PubMed ID: 38050530
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute effects of dietary phosphorus intake on markers of mineral metabolism in hemodialysis patients: post hoc analysis of a randomized crossover trial.
    Tsai WC; Wu HY; Chiu YL; Yang JY; Pai MF; Wu YR; Lin WY; Hung KY; Chien KL; Hsu SP; Peng YS
    Ren Fail; 2021 Dec; 43(1):141-148. PubMed ID: 33427559
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Management of bone and mineral metabolism disorders before the dialysis stage remains still perfectible. Data from the French Phosphorus and Calcium Survey Photo-Graphe].
    Jean G; Daugas É; Roth H; Drueke T; Bouchet JL; Hannedouche T; London G; Fouque D
    Nephrol Ther; 2017 Nov; 13(6):470-478. PubMed ID: 28843391
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hyperphosphatemia is a combined function of high serum PTH and high dietary protein intake in dialysis patients.
    Streja E; Lau WL; Goldstein L; Sim JJ; Molnar MZ; Nissenson AR; Kovesdy CP; Kalantar-Zadeh K
    Kidney Int Suppl (2011); 2013 Dec; 3(5):462-468. PubMed ID: 25019031
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
    Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
    Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Co-trending of parathyroid hormone and phosphate in patients receiving hemodialysis.
    Block G; Do TP; Collins AJ; Cooper KC; Bradbury BD
    Clin Nephrol; 2016 Mar; 85(3):142-51. PubMed ID: 26784912
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The challenge of controlling phosphorus in chronic kidney disease.
    Cannata-Andía JB; Martin KJ
    Nephrol Dial Transplant; 2016 Apr; 31(4):541-7. PubMed ID: 25770169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study.
    Fernández-Martín JL; Martínez-Camblor P; Dionisi MP; Floege J; Ketteler M; London G; Locatelli F; Gorriz JL; Rutkowski B; Ferreira A; Bos WJ; Covic A; Rodríguez-García M; Sánchez JE; Rodríguez-Puyol D; Cannata-Andia JB;
    Nephrol Dial Transplant; 2015 Sep; 30(9):1542-51. PubMed ID: 25920921
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mineral and bone metabolism markers and mortality in diabetic patients on haemodialysis.
    Martín-Carro B; Navarro-González JF; Ortiz A; Zoccali C; Floege J; Ferreira MA; Gorriz-Teruel JL; Carrillo-López N; Panizo S; Locatelli F; Ketteler M; London GM; Naves-Díaz M; Alonso-Montes C; Cannata-Andía JB; Fernández-Martín JL
    Nephrol Dial Transplant; 2023 Oct; 38(11):2589-2597. PubMed ID: 37349949
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mortality of combined serum phosphorus and parathyroid hormone concentrations and their changes over time in hemodialysis patients.
    Streja E; Wang HY; Lau WL; Molnar MZ; Kovesdy CP; Kalantar-Zadeh K; Park J
    Bone; 2014 Apr; 61():201-7. PubMed ID: 24486956
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trends of elevated parathormone serum titers in hemodialysis patients on intensive therapy for bone disease: a multicenter study.
    Karkar A; Sinha AK; Abdelrahman M; Mushtaque F; Awn NM; Qadi Y; Nassar M; Algareeb A; Taha MI; Abdulkader M; Sabry A; Souqiyyeh MZ; Shaheen FA
    Saudi J Kidney Dis Transpl; 2014 Nov; 25(6):1166-77. PubMed ID: 25394432
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dietary habits and counseling focused on phosphate intake in hemodialysis patients with hyperphosphatemia.
    Cupisti A; D'Alessandro C; Baldi R; Barsotti G
    J Ren Nutr; 2004 Oct; 14(4):220-5. PubMed ID: 15483782
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interventions for metabolic bone disease in children with chronic kidney disease.
    Hahn D; Hodson EM; Craig JC
    Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD008327. PubMed ID: 26561037
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association between CKD-MBD and mortality in older patients with advanced CKD-results from the EQUAL study.
    Magagnoli L; Cozzolino M; Caskey FJ; Evans M; Torino C; Porto G; Szymczak M; Krajewska M; Drechsler C; Stenvinkel P; Pippias M; Dekker FW; de Rooij ENM; Wanner C; Chesnaye NC; Jager KJ;
    Nephrol Dial Transplant; 2023 Oct; 38(11):2562-2575. PubMed ID: 37230954
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Progress in pharmacotherapy for the treatment of hyperphosphatemia in renal failure.
    Cernaro V; Longhitano E; Calabrese V; Casuscelli C; Di Carlo S; Spinella C; Gembillo G; Santoro D
    Expert Opin Pharmacother; 2023; 24(15):1737-1746. PubMed ID: 37527180
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of extended hours dialysis on markers of chronic kidney disease-mineral and bone disorder in the ACTIVE Dialysis study.
    Zhan Z; Smyth B; Toussaint ND; Gray NA; Zuo L; de Zoysa JR; Chan CT; Jin C; Scaria A; Hawley CM; Perkovic V; Jardine MJ; Zhang L
    BMC Nephrol; 2019 Jul; 20(1):258. PubMed ID: 31299919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.